Onco-Innovations Advances ONC010 Toward First-in-Human Testing with Integrated Manufacturing and Preclinical Strategy

Onco-Innovations Ltd. (CBOE CA: ONCO) (OTCQB: ONNVF) (FSE: W1H) is advancing its lead preclinical cancer candidate, ONC010, toward potential first-in-human testing by integrating drug manufacturing, nanoparticle formulation, analytical development, preclinical studies, and regulatory planning. The company’s strategy focuses on disrupting cancer cells’ DNA repair mechanisms, which could enhance the effects of radiation and certain chemotherapy treatments. This integrated approach is critical as it positions Onco-Innovations to potentially address significant unmet needs in oncology, where resistance to existing therapies remains a major challenge.

ONC010 combines the company’s PNKP-targeting small molecule A83B4C63 with a micellar nanoparticle delivery system intended to enhance drug exposure and tumor accumulation. By targeting PNKP, an enzyme involved in DNA repair, ONC010 aims to sensitize cancer cells to DNA-damaging treatments, potentially improving patient outcomes. The nanoparticle delivery system is designed to improve the drug’s pharmacokinetics and biodistribution, which could lead to better efficacy and reduced systemic toxicity.

The company has completed a 300-gram development batch of A83B4C63 at approximately 99.3% purity, a key milestone for ensuring consistent supply for preclinical and eventual clinical studies. Onco-Innovations has also advanced polymer manufacturing and identified a non-tin catalyst that could improve impurity control, which is essential for meeting regulatory standards. Additionally, the company is progressing pharmacokinetic, biodistribution, metabolism, and ADME studies to characterize the drug’s behavior in the body. These studies are foundational for determining safe and effective dosing in humans.

With an Australian subsidiary established, clinical-development partners engaged, and new scientific and clinical leadership in place, Onco-Innovations is working to integrate these activities into the manufacturing and regulatory package needed for a potential phase I/first-in-human study. This integration is crucial for navigating the complex regulatory landscape and ensuring that all components are aligned for a successful clinical trial application. The establishment of an Australian subsidiary may also provide strategic advantages, such as access to clinical trial infrastructure and potential research and development incentives.

The implications of this announcement are significant for Onco-Innovations and the broader oncology field. If successful, ONC010 could offer a novel approach to cancer treatment by combining targeted DNA repair inhibition with advanced delivery technology. This could potentially enhance the efficacy of existing therapies and provide new options for patients with solid tumors. Moreover, the progress toward first-in-human testing demonstrates the company’s commitment to translating preclinical research into clinical applications, which is a critical step in bringing new cancer treatments to market.

For investors, this update highlights Onco-Innovations’ progress in de-risking its lead candidate and moving closer to clinical validation. The completion of a large-scale development batch and the identification of a non-tin catalyst are tangible milestones that could increase confidence in the company’s manufacturing capabilities. As Onco-Innovations continues to advance ONC010, the potential for partnerships or licensing deals may also increase, given the promising preclinical data and the innovative mechanism of action.

To view the full article, visit https://ibn.fm/whdu9. For more information about Onco-Innovations, visit the company’s website at https://oncoinnovations.com/. The latest news and updates relating to ONNVF are available in the company’s newsroom at https://ibn.fm/ONNVF.